SG11202108519TA - Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia - Google Patents
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomiaInfo
- Publication number
- SG11202108519TA SG11202108519TA SG11202108519TA SG11202108519TA SG11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA SG 11202108519T A SG11202108519T A SG 11202108519TA
- Authority
- SG
- Singapore
- Prior art keywords
- thioeno
- pyridin
- amine compounds
- familial dysautonomia
- treating familial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805283P | 2019-02-13 | 2019-02-13 | |
| PCT/US2020/017430 WO2020167628A1 (en) | 2019-02-13 | 2020-02-10 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108519TA true SG11202108519TA (en) | 2021-09-29 |
Family
ID=69960696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108519TA SG11202108519TA (en) | 2019-02-13 | 2020-02-10 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220135586A1 (en) |
| EP (1) | EP3924049A1 (en) |
| JP (1) | JP2022520822A (en) |
| KR (1) | KR20210137040A (en) |
| CN (1) | CN113795304A (en) |
| AU (1) | AU2020222881A1 (en) |
| BR (1) | BR112021015853A2 (en) |
| CA (1) | CA3129067A1 (en) |
| CL (1) | CL2021002137A1 (en) |
| CO (1) | CO2021010598A2 (en) |
| EA (1) | EA202192170A1 (en) |
| IL (1) | IL285399A (en) |
| MX (1) | MX2021009667A (en) |
| PE (1) | PE20220139A1 (en) |
| SG (1) | SG11202108519TA (en) |
| WO (1) | WO2020167628A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022013856A (en) | 2020-05-13 | 2023-04-05 | Chdi Foundation Inc | Htt modulators for treating huntington's disease. |
| WO2022155427A1 (en) * | 2021-01-14 | 2022-07-21 | Georgetown University | Usp13 inhibitors and methods of use thereof |
| CN112920053B (en) * | 2021-02-01 | 2022-07-01 | 暨明医药科技（苏州）有限公司 | Preparation method of chiral alpha-methyl aromatic ethylamine |
| US20240051968A1 (en) * | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| WO2022169868A1 (en) * | 2021-02-05 | 2022-08-11 | Ptc Therapeutics Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| WO2022253294A1 (en) | 2021-06-03 | 2022-12-08 | 江苏恒瑞医药股份有限公司 | Pyridone compound having integrase inhibitory activity and pharmaceutical use thereof |
| EP4398987A1 (en) * | 2021-09-07 | 2024-07-17 | PTC Therapeutics, Inc. | Methods for treating neurogenerative diseases |
| EP4426708A1 (en) | 2021-11-04 | 2024-09-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
| WO2023212239A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023220439A1 (en) | 2022-05-12 | 2023-11-16 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023250316A1 (en) * | 2022-06-22 | 2023-12-28 | Ptc Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| WO2024036143A2 (en) * | 2022-08-09 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015005491A1 (en) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease |
| AU2016206589B2 (en) * | 2015-01-16 | 2020-09-10 | The General Hospital Corporation | Compounds for improving mRNA splicing |
-
2020
- 2020-02-10 SG SG11202108519TA patent/SG11202108519TA/en unknown
- 2020-02-10 EP EP20714017.9A patent/EP3924049A1/en active Pending
- 2020-02-10 CA CA3129067A patent/CA3129067A1/en active Pending
- 2020-02-10 KR KR1020217028864A patent/KR20210137040A/en not_active Application Discontinuation
- 2020-02-10 PE PE2021001329A patent/PE20220139A1/en unknown
- 2020-02-10 MX MX2021009667A patent/MX2021009667A/en unknown
- 2020-02-10 BR BR112021015853-7A patent/BR112021015853A2/en unknown
- 2020-02-10 JP JP2021547446A patent/JP2022520822A/en active Pending
- 2020-02-10 WO PCT/US2020/017430 patent/WO2020167628A1/en active Application Filing
- 2020-02-10 US US17/430,511 patent/US20220135586A1/en active Pending
- 2020-02-10 CN CN202080028449.2A patent/CN113795304A/en active Pending
- 2020-02-10 AU AU2020222881A patent/AU2020222881A1/en active Pending
- 2020-02-10 EA EA202192170A patent/EA202192170A1/en unknown
-
2021
- 2021-08-05 IL IL285399A patent/IL285399A/en unknown
- 2021-08-12 CO CONC2021/0010598A patent/CO2021010598A2/en unknown
- 2021-08-12 CL CL2021002137A patent/CL2021002137A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3924049A1 (en) | 2021-12-22 |
| JP2022520822A (en) | 2022-04-01 |
| CA3129067A1 (en) | 2020-08-20 |
| CO2021010598A2 (en) | 2021-08-30 |
| PE20220139A1 (en) | 2022-01-27 |
| US20220135586A1 (en) | 2022-05-05 |
| BR112021015853A2 (en) | 2021-10-05 |
| CL2021002137A1 (en) | 2022-02-25 |
| MX2021009667A (en) | 2021-12-10 |
| IL285399A (en) | 2021-09-30 |
| KR20210137040A (en) | 2021-11-17 |
| WO2020167628A1 (en) | 2020-08-20 |
| CN113795304A (en) | 2021-12-14 |
| AU2020222881A1 (en) | 2021-09-09 |
| EA202192170A1 (en) | 2021-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285399A (en) | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | |
| IL276802A (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| IL289290A (en) | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof | |
| IL287390A (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| IL287726A (en) | Aromatic compounds | |
| EP3801510A4 (en) | Methods for treating muscular dystrophies | |
| IL280661A (en) | -4 substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer | |
| SG11202111382RA (en) | Antibacterial agents & methods | |
| IL289416A (en) | Tricyclic compound, preparation method therefor and use thereof | |
| EP3999523A4 (en) | Melanophilin antisense oligonucleotides | |
| IL285204A (en) | Afabicin formulation, method for making the same | |
| EP4076669A4 (en) | Methods for treating glioblastoma | |
| GB202005952D0 (en) | Regalsystem, RegaLseitenwand und Seitenwandteil | |
| EP3789023A4 (en) | Composition for preventing or treating cognitive disorder-associated diseases, containing mumefural | |
| IL290319A (en) | Compound for combination treatment | |
| IL288797A (en) | Treatment for synucleinopathies | |
| PL4021900T3 (en) | 2,2,6-trimethyl-4,5-dihydro-3h-oxepine as aroma ingredient | |
| IL289141A (en) | 7,8-dihydro-4h-pyrazolo[4,3-c]azepine-6-one compounds | |
| EP3664786A4 (en) | Method for treating schnitzler's syndrome | |
| PT3921026T (en) | Carotenoids for treating or preventing nausea | |
| EP4069644C0 (en) | Sewage treatment machine | |
| IL289708A (en) | Immuno-oncology therapy using isoflavone compounds | |
| IL290506A (en) | Process for making [1.1.1] propellane | |
| IL289020A (en) | Antibacterial dosage regime using cannabinoids | |
| IL286015A (en) | Method for preparing tricyclic compound, and intermediate thereof |